NEW YORK (GenomeWeb) – About a year after launching a new version of its Decipher test for prostate cancer biopsy samples, GenomeDx is seeing encouraging adoption rates, the company said this week after publishing a new study supporting the prognostic power of its test.
Get the full story with
360Dx Premium
Only $95 for the
first 90 days*
360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.